ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

EXAMINATION OF THE RESPONSE TO A Alpha - 2 RECEPTOR AGONIST UTILIZED AS ANESTHETIC FOR THE PATIENTS USING Alpha-1 BLOCKERS

AUTHORS:

Dr Ghanwa Muzammil, Dr. Memoona Naeem, Dr Tooba Javaid

ABSTRACT:

Objective: The aim of this research work is to check the response to a α-2 receptor agonist utilized as an anesthetic for the patients undergoing prostrate surgery utilizing α1 blockers from a long duration. Methodology: 60 patients who were undergoing TURP (Trans-urethral Resection Prostate) or holmium laser prostate resection under the impact of SA (Spinal Anesthesia) separated into 2 groups; Group-N (35), which were not receiving α-1 blockers and Group-T (25), managed Tamsulosin for minimum one month prior to research work. We obtained the scores of bi-spectral indexes, scores of modified observer’s evaluation of sedation scale, HR (Heart Rate) and average BP under anesthesia utilizing dexmedetomidine for thirty minutes in the duration of the surgery. Results: Only one disparity discovered between groups was average BP fifteen minutes after the 1st dose of the dexmedetomidine through injection. We noted the disparities between the subjects of both groups at fifteen minute (Group-T: 98.20 ± 10.90 and Group-N: 88 ± 15.50 mmHg), twenty minute (Group-T: 97.80 ± 10.30 and Group-N: 85.40 ± 13 mmHg), at twenty-five minute (Group-T: 97.30 ± 11.40 and Group-N: 83.40 ± 11.80 mmHg) and at thirty minute (Group-T: 96.80 ± 11.10 and Group-N: 82.50 ± 11.50 mmHg). Conclusions: The utilization of the α-2 receptors is suitable during operation of the patients suffering from benign hyperplasia of prostate with the use of Tamsulosin, and findings showed no requirement to change the dose. Attentiveness with anesthesia including α-2 receptors maintained for the subjects utilizing Tamsulosin from long duration and the patients who never used Tamsulosin. KEYWORD: Tamsulosin, Anesthesia, Hyperplasia, Hypotension, Receptor. Dexmedetomidine, Prostate.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.